Journal article
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer
S Kopetz, A Grothey, R Yaeger, E Van Cutsem, J Desai, T Yoshino, H Wasan, F Ciardiello, F Loupakis, YS Hong, N Steeghs, TK Guren, HT Arkenau, P Garcia-Alfonso, P Pfeiffer, S Orlov, S Lonardi, E Elez, TW Kim, JHM Schellens Show all
New England Journal of Medicine | MASSACHUSETTS MEDICAL SOC | Published : 2019
Abstract
Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of pathway reactivation through epidermal growth factor receptor signaling. METHODS In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E–mutated metastatic colorectal cancer who had had disease progression after one or two previous regimens. Patients were randomly assigned in a 1:1:1 ratio to receive encorafenib, binimetinib, and cetuximab (triplet-therapy group); encorafenib and cetuximab (doublet-therapy group); or the investigators’ choice..
View full abstractGrants
Funding Acknowledgements
Funded by Array BioPharma and others